Aptose Biosciences

Aptose Biosciences

Company profile

About

Aptose Biosciences (TSX:APS), (NASDAQ:APTO) is a biotechnology firm focused on developing personalized therapies to address unmet medical needs in oncology, particularly in the treatment of life-threatening cancers. Aptose Biosciences operates with a keen eye on innovative research to advance the development of its pipeline products, which are designed to target the underlying mechanisms of cancer. The company is dedicated to pushing the boundaries of science to bring forward novel treatments that can offer better outcomes for patients battling cancer. Their objectives revolve around progressing their clinical trials, securing strategic partnerships, and advancing their research to bring transformative cancer therapies to the market.

Snapshot

1986Year founded

36Employees

Toronto, CanadaHead office

Loading Map...

Global footprint

Operations

All Locations

Toronto, CA

Products and/or services of Aptose Biosciences

Luxeptinib, a dual FLT3 and BTK inhibitor for acute myeloid leukemia and B-cell malignancies.
APTO-253, induces expression of the KLF4 gene, targeting acute myeloid leukemia and myelodysplastic syndromes.
Preclinical BTK inhibitors program targeting B-cell malignancies with a focus on overcoming resistance.
Preclinical FLT3 inhibitors program tailored for acute myeloid leukemia with a goal to evade current treatment resistance.
Collaborations with major pharmaceutical firms to enhance research, development, and commercialization of novel therapeutics.